Liu K, Hodes RJ, Weng NP. II, and 28.0 AEU for CIN III. The median percentage of immunoreactive dysplastic cells, as detected by immunohistochemistry, was significantly (p ?=? 0.024) lower in CIN I (45%) than in more severe dysplastic (CIN II 70%, CIN III 80%) lesions. In contrast, no differences were seen in the enzymatic activity detected by the TRAP assay among the different dysplastic lesions. Conclusions: These data indicate that, using a molecular extra situ method, the telomerase activity of inflammatory and non-dysplastic elements masks the expected differences between moderate and severe dysplasia. Conversely, an in situ approach permits the accurate identification of telomerase positive dysplastic cells. Prevalence of human papillomavirus in cervical malignancy: a worldwide prospective. International biological study on cervical malignancy (IBSCC) study group. J Natl Malignancy Inst 1995;87:796C802. [PubMed] [Google Scholar] 2. Landis SH, Murray T, Bolden S, Malignancy statistics, 1999. CA Malignancy J Clin 1999;49:8C31. [PubMed] [Google Scholar] 3. Pinto AP, Crum CP. Natural history of cervical neoplasia: defining progression and its result. Clin Obstet Gynecol 2000;43:352C62. [PubMed] [Google Scholar] 4. Mitchell MF, Tortolero-Luna G, Wright T, Cervical human papillomavirus contamination and intraepithelial neoplasia: a review. J Natl Malignancy Inst Monogr 1996;21:17C25. [PubMed] [Google Scholar] 5. zur Hausen H. Papillomaviruses and malignancy: from basic studies to clinical applicationNat Rev Malignancy 2002;2:342C50. [PubMed] [Google Scholar] 6. Arends MJ, Buckey CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 1998;51:96C103. [PMC free article] [PubMed] [Google Scholar] 7. Sano T, Oyama T, Kashiwabara K, Expression status of p16 protein is usually associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741C8. [PMC free article] [PubMed] [Google Scholar] 8. Takakura M, Kyo S, Kanaya T, Expression of human telomerase subunits and correlation with telomerase activity in cervical malignancy. Malignancy Res 1998;58:1558C61. [PubMed] [Google Scholar] 9. Kim NW, Piatyszek MA, Rainey WE, Specific association of human telomerase activity with immortal cells and malignancy. Science 1994;266:2011C15. [PubMed] [Google Scholar] 10. Shay JW, Bacchetti S. A survey of telomerase activity in human malignancy. Eur J Malignancy 1997;33:787C91. [PubMed] [Google Scholar] 11. Feng J, Funk WD, Wang SS, The RNA component of human telomerase. Science 1995;269:1236C41. [PubMed] [Google Scholar] 12. Harrington Sipeimine L, McPhail T, Mar V, A mammalian telomerase-associated protein. Science 1997;275:973C7. [PubMed] [Google Scholar] 13. Nakamura TM, Morin GB, Chapman KB, Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955C9. [PubMed] [Google Scholar] 14. Meyerson M, Counter CM, Eaton EN, hEST2, the putative human telomerase catalytic subunit gene, is usually upregulated in tumor cells and during immortalization. Cell 1997;90:785C95. [PubMed] [Google Scholar] 15. Kurman RJ, Solomon D. The Bethesda system for reporting cervical/vaginal cytologic diagnoses: definitions, criteria, and explanatory notes for terminology and specimen adequacy. New York: Springer-Verlag, 1994. 16. Fedriga R, Gunelli R, Nanni O, Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. Neoplasia 2001;3:446C50. [PMC free article] [PubMed] [Google Scholar] 17. Sanchini MA, Bravaccini S, Medri L, Urine telomerase: an important marker in the diagnosis of bladder malignancy. Neoplasia 2004;6:234C9. [PMC free article] [PubMed] [Google Scholar] 18. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 1995;23:3794C5. [PMC free article] [PubMed] [Google Scholar] 19. Kyo S, Takakura M, Tanaka Sipeimine M, Telomerase activity in cervical malignancy is usually quantitatively unique from that in its precursor lesions. Int J Malignancy 1998;79:66C70. [PubMed] [Google Scholar] 20. Pao CC, MRPS31 Tseng CJ, Lin Sipeimine CY, Differential expression of telomerase activity in human cervical malignancy and cervical intraepithelial neoplasia lesions. Clin Oncol 1997;15:1932C7. [PubMed] [Google Scholar] 21. Snijders PJ, van Duin M, Walboomers JM, Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Malignancy Res 1998;58:3812C18. [PubMed] [Google Scholar] 22. Mutirangura A, Sriuranpong V, Termrunggraunglert W, Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. Br J Malignancy 1998;78:933C9. [PMC free article] Sipeimine [PubMed] [Google Scholar] 23. Reesink-Peters N,.